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15-Deoxy-12,14-prostaglandin J2 (15dPGJ2) has been
proposed recently as a potent anti-inflammatory agent.
However, the mechanisms by which 15dPGJ2 mediates
its therapeutic effects in vivo are unclear. We demon-
strate that 15dPGJ2 at micromolar (2.5–10 M) concen-
trations induces the expression of heme oxygenase-1
(HO-1), an anti-inflammatory enzyme, at both mRNA
and protein levels in human lymphocytes. In contrast,
troglitazone and ciglitazone, two thiazolidinediones
that mimic several effects of 15dPGJ2 through their
binding to the peroxisome proliferator-activated recep-
tor (PPAR)-, did not affect HO-1 expression, and the
positive effect of 15dPGJ2 on this process was mimicked
instead by other cyclopentenone prostaglandins (PG),
such as PGD2 (the precursor of 15dPGJ2) and PGA1 and
PGA2 which do not interact with PPAR-. Also, 15dPGJ2
enhanced the intracellular production of reactive oxy-
gen species (ROS) and increased xanthine oxidase activ-
ity in vitro. Inhibition of intracellular ROS production
by N-acetylcysteine, TEMPO, Me2SO, 1,10-phenanthro-
line, or allopurinol resulted in a decreased 15dPGJ2-
dependent HO-1 expression in the cells. Furthermore,
buthionine sulfoximine, an inhibitor of reduced glu-
tathione synthesis, or Fe2/Cu2 ions enhanced the pos-
itive effect of 15dPGJ2 on HO-1 expression. On the other
hand, the inhibition of phosphatidylinositol 3-kinase or
p38 mitogen-activated protein kinase, or the blockade of
transcription factor NF-B activation, hindered
15dPGJ2-elicited HO-1 expression. Collectively, the
present data suggest that 15dPGJ2 anti-inflammatory
actions at pharmacological concentrations involve the
induction of HO-1 gene expression through mechanisms
independent of PPAR- activation and dependent on
ROS produced via the xanthine/xanthine oxidase system
and/or through Fenton reactions. Both phosphatidyli-
nositol 3-kinase and p38 mitogen-activated protein
kinase signaling pathways also appear implicated in
modulation of HO-1 expression by 15dPGJ2.
15-Deoxy-12,14-prostaglandin J2 (herein referred to as
15dPGJ2)
1 is an active metabolite derived from PGD2 dehydra-
tion in vivo, which is physiologically present in body fluids at
1012 to 109 M concentrations. However, 15dPGJ2 amounts
become highly increased in several pathological conditions,
such as infection and inflammation (1, 2). PGD2 and thus
15dPGJ2 are abundantly produced by mast cells, platelets, and
alveolar macrophages, and 15dPGJ2 has been proposed as a
key immunoregulatory lipid mediator (3–5). A number of its
actions seem to be exerted through its binding to peroxisome
proliferator-activated receptor (PPAR)- (6–8). The PPARs are
nuclear hormone receptors that can bind, normally as het-
erodimers with the retinoid X receptor, to peroxisome prolif-
erator-responsive elements (AGGTCAnAGGTCA) present in
the promoters of their target genes to activate their transcrip-
tion (9). A variety of immune cells, including T and B lympho-
cytes as well as macrophages, have been found to express
PPAR- and their activation to be regulated via PPAR--de-
pendent mechanisms (7, 8, 10). However, it has been also
demonstrated that other effects of 15dPGJ2 are exerted inde-
pendently of PPAR- (reviewed in Ref. 1), such as the activa-
tion of mitogen-activated protein (MAP) kinase cascades in
astrocytes and preadipocytes, which is mediated by reactive
oxygen species (ROS) (11), the induction of caspase-dependent
apoptosis in eosinophils and neutrophils (12), the inhibition of
cell adhesion and the oxidative burst in neutrophils (13), and
the induction of the expression of proinflammatory genes in
monocytes/macrophages derived from PPAR-deficient embry-
onic stem cells (14, 15).
The role of 15dPGJ2 in the modulation of inflammation is
nevertheless complex, because this prostaglandin exhibits both
anti-inflammatory and proinflammatory functions and thus
remains the subject of intensive investigation. In this context,
15dPGJ2 has been shown to inhibit the expression of inducible
NO synthase, as well as tumor necrosis factor- and interleu-
kin-1 production in mouse and human macrophages, thus
suggesting a role for 15dPGJ2 in the inhibition of inflammation
(16, 17). Available data also suggest that the induction of heme
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oxygenase-1 (HO-1) expression elicited by 12-PGJ2 in rat ba-
sophilic leukemia cells and other cell types involved in the
inflammatory response may play an important role in the fate
of heme liberated during inflammation, and thus an anti-in-
flammatory role has been ascribed to 12-PGJ2 (18). In this
view, 15dPGJ2 has been suggested to play a feedback regula-
tory role in the resolution phase of inflammation and hence is
considered as a potential therapeutic target for the treatment
of inflammatory diseases (1). However, caution must be taken
in assigning a solely anti-inflammatory role to 15dPGJ2, be-
cause there is also experimental evidence that 15dPGJ2 can
induce the synthesis of the type II-secreted proinflammatory
mediators phospholipase A (6) and COX-2 in smooth muscle
(20) and epithelial cells (21). Moreover, it has been shown
recently (22) that in stimulated human T lymphocytes,
15dPGJ2 induces a significant increase in interleukin-8 produc-
tion through the activation of a MAP kinase- and NF-B-de-
pendent signaling pathway.
Heme oxygenase is a widely distributed enzyme in mamma-
lian tissues whose main function is associated with the degra-
dation of heme to biliverdin, iron, and carbon monoxide (23).
Three distinct isoforms of this protein have been characterized,
two of which (HO-2 and HO-3) are constitutively expressed,
whereas the third (HO-1) displays inducible expression (24).
Several pathological states, including hypoxia, atherosclerosis,
and inflammation, have been found to be accompanied by over-
expression of the HO-1 gene and increased HO-1 enzyme ac-
tivity (25–27). Over the past few years, several studies (28, 29)
have revealed the important function of HO-1 as a cytoprotec-
tive mechanism against oxidative insults, derived from the
antioxidant activities of biliverdin and bilirubin and from the
anti-inflammatory action of carbon monoxide. In this context, a
common denominator characterizing the prompt stimulation of
HO-1 expression occurring under the above conditions is a
drastic change in the intracellular redox status accompanied by
a transient decrease in cytosolic reduced glutathione levels
(25, 30).
Recent studies have illustrated that 15dPGJ2 induces HO-1
expression in a variety of cells, including hepatocytes (31),
cardiac myocytes (32), microglial cells (33), murine macro-
phages (34), and rat basophilic leukemia cells (18). Also, it has
been shown that 15dPGJ2 is able to induce apoptosis in mouse
T cells and to inhibit T cell activation (7, 8, 35). However, the
effect of 15dPGJ2 on HO-1 gene expression has not yet been
analyzed in human lymphocytes, and in general there is no
information available on the signaling mechanisms modulating
HO-1 synthesis in these cells. In the present study, we have
investigated the effect of 15dPGJ2, using pharmacological con-
centrations, on the expression of HO-1 in human lymphocytes,
and the involvement of ROS-dependent specific pathways in
this process. We present clear evidence that 15dPGJ2 at micro-
molar (2.5–10 M) levels induces an increase of HO-1 mRNA
and protein levels in human lymphocytes, a process that is
prevented by scavengers of ROS, and we postulate that ROS
derived from both Fenton chemistry and the xanthine/xanthine
oxidase system are implicated in the induction of HO-1 gene
expression in this cell type. In addition, we provide evidence of
phosphatidylinositol 3-kinase (PI3-kinase) and p38 MAP ki-
nase acting as mediators of 15dPGJ2 effects on HO-1 expres-
sion and of the involvement of the transcription factor NF-B in
this process. These results contribute to shed some light on the
mechanisms whereby 15dPGJ2 modulates leukocyte functions
through PPAR--independent pathways.
EXPERIMENTAL PROCEDURES
Materials—15dPGJ2, SN50 (AAVALLPAVLLALLAPVQRKRQKL-
MP), and SN50M (AAVALLPAVLLALLAPVQRNGQKLMP) peptides
were obtained from Biomol (Plymouth Meeting, PA). Troglitazone, cigli-
tazone, Wy14,643, PGD2, PGA1, and PGA2 were products of Cayman
Chemical (Ann Arbor, MI). Sodium arsenite, actinomycin D, cyclohex-
imide, N-acetylcysteine (NAC), buthionine sulfoximine (BSO), TEMPO,
Me2SO, 1,10-phenanthroline, allopurinol, 4-hydroxy-3-methoxyaceto-
phenone (HMAP), probenecid, luminol, lucigenin, ketoconazole, rote-
none, genistein, staurosporine, cyclosporin A, okadaic acid, wortman-
nin, and LY294002 were purchased from Sigma. SB203580 and
PD098059 were products of Calbiochem, and RPMI 1640 medium was
obtained from Biomedia (Boussens, France).
Isolation and Culture of Human Lymphocytes—Human peripheral
blood lymphocytes were isolated from fresh heparinized blood of
healthy human donors, after informed consent, by Ficoll-Paque (Amer-
sham Biosciences) gradient centrifugation followed by hypotonic lysis of
residual erythrocytes (36). After elimination of adherent cells by incu-
bation on plastic dishes for 45 min at 37 °C, lymphocytes were cultured
in RPMI 1640 medium supplemented with 10% (v/v) fetal bovine serum,
2 mM L-glutamine, 100 units/ml penicillin, and 100 g/ml streptomycin
and maintained at 37 °C in an atmosphere of 5% CO2. In all control
experiments in which 15dPGJ2 was omitted, its vehicle (0.1% Me2SO)
was added instead.
Western Blotting Analysis of HO-1 Protein Levels—Cells were rinsed
once with ice-cold phosphate-buffered saline, resuspended in a lysis
solution containing 50 mM Tris-HCl (pH 7.4), 10 mM EDTA, 50 mM NaF,
10% glycerol, 1% Triton X-100, 10 g/ml leupeptin, 10 g/ml aprotinin,
and 1 mM phenylmethylsulfonyl fluoride, and maintained on ice for 30
min. Then the cells were disrupted by sonication on ice and, after
centrifugation at 12,000 g for 5 min at 4 °C, the protein concentration
in the supernatant was determined by the Bradford method (37), using
bovine serum albumin as a standard. Cell lysate proteins (38) were
boiled in Laemmli loading buffer, resolved by SDS-PAGE, and trans-
ferred to polyvinylidene difluoride membranes (Pall, Madrid, Spain).
Blots were probed with rabbit polyclonal antibodies to HO-1 (Santa
Cruz Biotechnology, Santa Cruz, CA) at a 1:1000 dilution, and horse-
radish peroxidase-conjugated secondary antibodies to rabbit IgG
(Sigma) were used at a 1:5000 dilution to detect the 32-kDa HO-1 band
by subsequent enhanced chemiluminescence (39). To verify even pro-
tein loading, the blots were subsequently stripped and reprobed with
rabbit polyclonal antibodies against -actin (42 kDa) from Santa Cruz
Biotechnology (1:1000 dilution). Relative protein levels were deter-
mined by scanning densitometry analysis using the Scion Image soft-
ware. Values given below each panel in Figs. 1–4 and 6–9 represent the
mean (in relative units), normalized to control values, of at least three
experiments performed with similar results.
RT-PCR Analysis of HO-1 mRNA Levels—Total cellular RNA was
extracted using the phenol-guanidinium isothiocyanate method (40).
Reverse transcription to cDNA was performed at 37 °C for 1 h in 24 l
of reaction mixture containing 2 g of RNA, the four dNTPs at 1 mM
each, 2.5 M random hexamer primers, 1 mM dithiothreitol, 20 units of
RNAsin ribonuclease inhibitor, and 100 units of Moloney murine leu-
kemia virus reverse transcriptase (Promega, Madison, WI). PCR am-
plification of cDNA (4) was performed in 10 l of reaction using the
following HO-1-specific primers at 0.5 M each: forward, 5-TTCT-
TCACCTTCCCCAAC-3, and reverse, 5-GCATAAAGCCCTACAG-
CAAC-3), the four dNTPs at 400 M each, 5% Me2SO, and 1 unit of
TaqDNA polymerase (Roche Diagnostics). After an initial denaturation
step at 94.5 °C for 5 min, PCR was performed for a total of 45 cycles,
each at 94.5 °C for 1 min, 60 °C for 2 min, and 72 °C for 3 min. To ensure
that equal amounts of cDNA were added to the PCRs, the glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH) gene was amplified as a
control, using the following primers: forward, 5-CCACCCATG-
GCAAATTCCATGGC-3, and reverse, 5-TCTAGACGGCAGGTCAG-
GTCCACC-3. PCR-amplified bands (HO-1, 365 bp; GADPH, 600 bp)
were visualized on 1% agarose gels stained with ethidium bromide
using the BioDoc-ItTM system (Ultraviolet Products, Upland, CA).
ROS Production Assay—2,7-Dichlorohydrofluorescein diacetate
(DCFDA, from Sigma) was used as an indicator of the amount of
intracellular ROS (41). Briefly, 5  106 human lymphocytes were sus-
pended in 1 ml of KR-Hepes and incubated in the presence of 2.5 M
DCFDA and 2.5 mM probenecid (an inhibitor of anion membrane trans-
port) at 37 °C for 1 h in the dark. The cells were then rinsed twice with
KR-Hepes plus 2.5 mM probenecid, and after addition of the stimulus,
fluorescence intensity was measured for up to 4 h in a Wallac 1420
VICTOR2TM spectrofluorometer, using excitation and emission wave-
lengths of 485 and 535 nm, respectively. In addition, luminol- and
lucigenin-enhanced chemiluminescence assays were performed as described
(42) for the measurement of total ROS and superoxide anion (O2
.) levels,
respectively.
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Xanthine Oxidase Activity Assay—Xanthine oxidase activity was de-
termined by monitoring the rate of uric acid formation (43). Assays were
performed using different concentrations of cow milk xanthine oxidase
(Roche Diagnostics) in a reaction mixture (1 ml) containing 0.1 mM
xanthine and 0.1 mM EDTA in 50 mM phosphate potassium buffer (pH
7.4). The reactions were carried out at 37 °C and stopped at 20 min by
the addition of 100 l of 100% (w/v) trichloroacetic acid. After centrif-
ugation at 10,000  g for 15 min, the uric acid produced was measured
in the supernatants on the basis of the change in the absorbance at
293 nm.
RESULTS
15dPGJ2 Induces HO-1 Gene Expression in Human Lympho-
cytes—Preliminary experiments were addressed to analyze the
effect of 15dPGJ2 on the expression of HO-1 in human lympho-
cytes. Fig. 1A shows that 10 M 15dPGJ2 elicited the synthesis
of HO-1 protein in a time-dependent manner. This effect was
noticeable at 3 h after 15dPGJ2 addition, reaching its maximal
expression at 12 h of treatment and maintaining at this level
during the rest of the experiment (up to 30 h). The induction of
HO-1 protein expression correlated with increased levels of
HO-1 mRNA, which became detectable as early as 1 h after
treatment with 15dPGJ2 (Fig. 1B). A dose-dependent analysis
showed that HO-1 gene expression was induced at both protein
(Fig. 1C) and mRNA (Fig. 1D) levels by concentrations of
15dPGJ2 in the 2.5–10 M range. In order to study the molec-
ular mechanisms implicated in 15dPGJ2-dependent HO-1 in-
duction, human lymphocytes were treated with actinomycin D,
a well known inhibitor of transcription, and cycloheximide, an
established inhibitor of protein synthesis, before the addition of
15dPGJ2 (Fig. 1, E and F). As expected, the pretreatment of
lymphocytes with actinomycin D blocked both HO-1 protein
and mRNA synthesis, whereas cycloheximide inhibited HO-1
protein expression but did not affect mRNA expression, sug-
gesting that 15dPGJ2 induction of HO-1 expression is exerted
at the transcriptional level. As reported, 15dPGJ2 can act on
cells through either PPAR--dependent or -independent mech-
anisms (13, 15). To address which was the case for HO-1 ex-
pression in human lymphocytes, we treated these cells with the
PPAR- natural ligand, 15dPGJ2, or with the synthetic PPAR-
agonists, troglitazone and ciglitazone, and well as with the
PPAR non-related inducer of HO-1 expression, sodium arsenite
(44). Although both 15dPGJ2 and arsenite and clearly pro-
moted HO-1 gene expression at both protein and mRNA levels
(Fig. 2, A and B, respectively), neither troglitazone nor ciglita-
zone affected these processes. We also observed that Wy14,643,
a PPAR- agonist, was unable to promote HO-1 protein or
mRNA expression in these cells (Fig. 2, A and B). These data
strongly suggested that the induction of HO-1 expression by
15dPGJ2 in human lymphocytes is exerted by a mechanism
independent of PPAR activation.
Because the effects of cyclopentenone prostaglandins, like
15dPGJ2 and A series prostaglandins, are mediated by the
reactive ,-unsaturated carbonyl group in their cyclopentane
ring (45), subsequent experiments were addressed to study the
effect of prostaglandins A, which do not bind to any member of
the PPAR subfamily of receptors, on HO-1 expression. Fig. 2, C
and D, illustrates that both HO-1 protein and mRNA levels
were increased by both PGA1 and PGD2, the precursor of
15dPGJ2 (46), in human lymphocytes. However, the effect of
PGA2 on HO-1 expression only was only detected on mRNA
levels but not on protein levels.
15dPGJ2 Induces HO-1 Expression through Changes in In-
tracellular ROS Levels—HO-1 expression has been shown to
FIG. 1. Induction by 15dPGJ2 of
HO-1 expression in human lympho-
cytes. Cells were incubated at 37 °C with
10 M 15dPGJ2 for the indicated times (A
and B) or at the indicated doses for 18 (C)
or 4 h (D), or else were preincubated in
the absence or presence of 5 g/ml actino-
mycin D (Act D) or 5 g/ml cycloheximide
(CHX) for 1 h, and then treated or not
with 5 M 15dPGJ2 for 18 (E) or 4 h (F).
Thereafter, the cells were lysed, and
HO-1 and -actin protein levels were de-
termined by Western blotting analysis (A,
C, and E), and HO-1 and GAPDH mRNA
levels were analyzed by RT-PCR (B, D,
and F).
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become up-regulated in response to cellular stress or changes
in the intracellular redox status in endothelial cells and fibro-
blasts (25, 30, 47). We thus tested whether the positive effect of
15dPGJ2 on HO-1 expression was modified by NAC, a well
known scavenger of ROS. With this goal, cultured lymphocytes
were pretreated with NAC prior to the addition of 15dPGJ2 to
the medium. Fig. 3A illustrates that 0.5 mM NAC inhibited
15dPGJ2-dependent HO-1 expression by about 60% and that
this inhibition was complete at a dose of 5 mM NAC. Because it
has also been described that a transient decrease in cellular
reduced glutathione levels promotes HO-1 synthesis in a vari-
ety of mammalian (including human) cell types (48, 49), this
observation prompted us to examine the effect of the pretreat-
ment with BSO, an inhibitor of glutathione synthesis, on
15dPGJ2-induced HO-1 expression. As shown in Fig. 3B, cells
preincubated with BSO experienced a significantly higher
15dPGJ2-induced HO-1 expression than did previously un-
treated cells. BSO, however, was by itself unable to induce
HO-1 expression. To assess further whether 15dPGJ2-depend-
ent HO-1 expression was mediated by intracellular ROS, hu-
man lymphocytes were treated with two well known ROS
scavengers, such as TEMPO, a superoxide dismutase mimetic
for O2
., and Me2SO at a concentration (0.5%) where it acts as a
scavenger of hydroxyl radicals (OH) (50, 51). As shown in Fig.
4, both of these reagents were found to drastically cancel
15dPGJ2-elicited HO-1 expression. Subsequent experiments
were addressed to analyze whether 15dPGJ2 was able to alter
intracellular ROS levels in lymphocytes. With this goal, the
cells were treated with 15dPGJ2, and changes in the intracel-
lular levels of ROS were detected using the ROS-sensitive
fluorescent probe DCFDA, an established sensor of oxidative
stress (41). Fig. 5 shows that in human lymphocytes incubated
with 15dPGJ2, a higher production of ROS took place than in
control cells treated with vehicle alone (0.1% Me2SO), in which
an unspecific increase of ROS levels was observed. It must be
mentioned that Me2SO, when used at a 0.1% concentration,
neither affected cell viability nor did it act as an ROS scavenger
(data not shown). In additional experiments performed using
luminol- or lucigenin-enhanced chemiluminescence to measure
total ROS and O2
. levels, respectively, similar results were
obtained regarding 15dPGJ2 effects (data not shown). This
set of data indicates that intracellular ROS are involved in
the induction of HO-1 expression by 15dPGJ2 in human
lymphocytes.
Effect of Fe2/Cu2 Ions on 15dPGJ2-induced HO-1 Expres-
sion—As in other cell types, in lymphocytes the most likely
mode of intracellular production of highly active oxygen spe-
cies, such as OH, is via Fenton chemistry, which involves the
reduction of H2O2 by Fe
2 or Cu2 ions according to the reac-
tion: H2O2  Fe
2 u OH  OH  Fe3 (52). We thus
analyzed whether chemical species generated from H2O2
through Fenton reactions could affect 15dPGJ2-dependent
HO-1 expression. Fig. 6 illustrates that the addition of Fe2/
Cu2 ions to lymphocytes prior to the treatment with 15dPGJ2
notably enhanced HO-1 expression. Noteworthy, when the cells
were incubated with Fe2/Cu2 alone, a detectable expression
of HO-1 protein also took place, although at lower levels than in
the simultaneous presence of 15dPGJ2. By contrast, the pre-
treatment of cells with 1,10-phenanthroline, a chelator of cop-
per and iron ions, resulted in the cancellation of 15dPGJ2-
elicited HO-1 synthesis. These data indicate that ROS
generated via Fenton reactions could constitute an efficient
mechanism mediating the positive effect of 15dPGJ2 on HO-1
induction.
Effect of the Xanthine/Xanthine Oxidase System on 15dPGJ2-
induced HO-1 Expression—The NADPH oxidase complex, the
xanthine/xanthine oxidase system, and the mitochondrial res-
piratory chain are largely accredited as generator systems of
intracellular ROS in most cell types (53, 54). When the xan-
thine oxidase inhibitor, allopurinol (55), was added to lympho-
cyte cultures prior to 15dPGJ2 treatment, the expression of
HO-1 became significantly decreased in a dose-dependent man-
FIG. 2. Effect of synthetic PPAR agonists and cyclopentenone prostaglandins on HO-1 expression in human lymphocytes. Cells
were incubated at 37 °C in the absence or presence of 5 M 15dPGJ2, 25 M troglitazone, 40 M ciglitazone, 25 M Wy14,643, 5 M sodium arsenite
(AsO2Na), 10 M PGD2, 15 M PGA1 or 25 M PGA2 for 18 (A and C) or 4 h (B and D). The cells were then lysed, and HO-1 and -actin protein
levels were determined by Western blotting analysis (A and C), and HO-1 and GAPDH mRNA levels were analyzed by RT-PCR (B and D).
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ner (Fig. 7A). However, other inhibitors of enzyme systems
involved in ROS production, like rotenone (an inhibitor of mi-
tochondrial electron transport), ketoconazole (a cytochrome
P-450 inhibitor) and HMAP (an NADPH oxidase inhibitor), did
not affect 15dPGJ2-dependent HO-1 expression (data not
shown). The inhibitory effect of allopurinol suggested the pos-
sibility that 15dPGJ2 induction of HO-1 expression could be
mediated by the activation of the xanthine/xanthine oxidase
system. To test this hypothesis, we tried to assay xanthine
oxidase activity in lymphocytes in the absence and presence of
15dPGJ2. However, this enzyme activity was too low in this cell
type, as reported previously (56), to allow reliable measure-
ments by using our methodology. A different in vitro experi-
mental approach was thus used, in which the effect of 15dPGJ2
on a commercial preparation of xanthine oxidase was tested. It
was found that upon incubation with 15dPGJ2, the activity of
this enzyme became notably increased, by about 10-fold (Fig.
7B). Present data thus suggest that a potential source for the
ROS involved in 15dPGJ2-dependent HO-1 expression in hu-
man lymphocytes could be xanthine oxidase.
15dPGJ2 Induction of HO-1 Expression Is Mediated by PI3-
kinase and MAP Kinase but Not by Protein Phosphatases 2A
and 2B—The participation of these signaling molecules on the
15dPGJ2 positive effect on HO-1 synthesis was analyzed by
using specific pharmacological inhibitors. A relationship be-
tween ROS intracellular levels and the activity of both PI3-
kinase and MAP kinases is well established (42, 57), and thus
subsequent experiments were addressed to investigate the po-
tential contribution of their mediated signaling pathways on
15dPGJ2-dependent HO-1 expression. Toward this end, human
lymphocytes were pretreated with wortmannin or LY294002,
two inhibitors of PI3-kinase, and then stimulated with
15dPGJ2 for 4 h (corresponding to the half-life of wortmannin
in the culture medium). Fig. 8A illustrates that both PI3-kinase
inhibitors significantly blocked the 15dPGJ2 induction of HO-1
protein expression. Likewise, the potential involvement of
MAP kinase pathways in the induction of HO-1 expression by
15dPGJ2 was addressed by using SB203580, a p38 MAP kinase
inhibitor, and PD098059, an inhibitor of MEK1/2, the up-
FIG. 3. Effect of NAC and BSO on 15dPGJ2-dependent HO-1 expression in human lymphocytes. Cells were preincubated at 37 °C for
1 h with the indicated doses of NAC for 1 h and then treated or not with 5 M 15dPGJ2 for 18 h (A) or preincubated with 25 M BSO for 1 h, and
then treated with the indicated doses of 15dPGJ2 for 18 h (B). Thereafter, the cells were lysed, and HO-1 and -actin protein levels were determined
by Western blotting analysis.
FIG. 4. Effect of ROS scavengers on 15dPGJ2-dependent HO-1
expression in human lymphocytes. Cells were preincubated at
37 °C in the absence or presence of 100 M TEMPO or 0.5% Me2SO for
2 h and then treated or not with 3 M 15dPGJ2 for 18 h. Thereafter, the
cells were lysed, and HO-1 and -actin protein levels were determined
by Western blotting analysis.
FIG. 5. Effect of 15dPGJ2 on intracellular ROS levels in human
lymphocytes. Cells were preincubated at 37 °C with 2.5 M DCFDA
for 1 h. They were then washed twice, and vehicle (0.1% Me2SO) or
15dPGJ2 (9) was added, and the fluorescence at 535 nm was recorded
for different times up to 4 h. Plotted values are the mean  S.E. from
three separate experiments.
FIG. 6. Effect of Fe2/Cu2 ions on 15dPGJ2-dependent HO-1
expression in human lymphocytes. Cells were preincubated at
37 °C in the absence or presence of 20 M 1,10-phenanthroline (1,10-
Phe) or FeSO4 plus CuSO4 at the indicated doses for 1 h, and then
treated or not with 3 M 15dPGJ2 for 18 h. Thereafter, the cells were
lysed, and HO-1 and -actin protein levels were determined by Western
blotting analysis.
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stream activator of extracellular signal-regulated kinases 1
and 2 (ERK1/2). When these reagents were added to cultures
prior to treatment with 15dPGJ2, it was found that whereas
SB203580 (at 5–10 M) canceled 15dPGJ2-promoted HO-1 pro-
tein expression, PD098059 (up to 50 M) was without effect on
this process (Fig. 8B). Similarly, when the effect of these com-
pounds was tested on 15dPGJ2-dependent HO-1 mRNA syn-
thesis, both LY294002 and SB203580 abolished this process,
whereas PD098059 lacked any inhibitory action (Fig. 8C). Fi-
nally, the effects of genistein and staurosporine (two nonspe-
cific inhibitors of protein tyrosine kinases and protein kinase C,
respectively), as well as of cyclosporin A and okadaic acid (two
specific inhibitors of protein phosphatases PP-2B and PP-1/2A,
respectively), were also tested. It was found that all these
compounds failed to inhibit 15dPGJ2-dependent HO-1 protein
synthesis (data not shown). Therefore, our data indicate that
activation of the PI3-kinase and p38 MAP kinase pathways are
upstream signaling events required for 15dPGJ2-dependent
HO-1 expression.
15dPGJ2 Induction of HO-1 Expression Is Dependent on
NF-B—15dPGJ2 has been reported to elicit the activation of
the transcription factor NF-B in human T cells (22). Also, an
NF-B-binding motif has been found in the promoter of the
mouse Ho-1 gene (58). In order to assess whether NF-B acti-
vation is essential for the induction of HO-1 expression by
15dPGJ2 in human lymphocytes, the NF-B-blocking peptide
SN50 was used. This peptide inhibits nuclear translocation and
thereby the intranuclear functions of NF-B (59, 60). Fig. 9
clearly shows that in human lymphocytes treated with the
SN50 peptide prior to the addition of 15dPGJ2, induction of
HO-1 protein expression was reduced by about 4-fold. As a
control, the effect of the mutant SN50 peptide (SN50M), which
is able to bind NF-B but does not inhibit its nuclear translo-
cation, was also tested. As also shown in Fig. 9, the mutant
SN50M peptide had no effect on induction of HO-1 synthesis by
15dPGJ2. These data indirectly suggest that 15dPGJ2-depend-
ent HO-1 expression in human lymphocytes is dependent on
transcriptional activation by NF-B.
DISCUSSION
Prostaglandin 15dPGJ2 is considered to be an anti-inflam-
matory molecule with therapeutic properties (1, 16, 17), which
regulates cytokine secretion (8, 61) and induces apoptosis in T
lymphocytes (7, 35). We have experimentally tested the possi-
bility that 15dPGJ2 could exert its anti-inflammatory effects in
human lymphocytes through the expression of HO-1, a potent
immunomodulator molecule (27, 28). The present study docu-
ments for the first time that 15dPGJ2 elicits at micromolar
(2.5–10 M) concentrations in human lymphocytes a series of
events involving the induction of HO-1 gene expression at both
mRNA and protein levels. This induction is sensitive to the
inhibitor of transcription, actinomycin D, and to the protein
synthesis inhibitor, cycloheximide, indicating that 15dPGJ2
activates HO-1 gene expression through modulation of tran-
scription and/or stabilization of HO-1 mRNA. We also provide
experimental evidence that 15dPGJ2-dependent HO-1 induc-
tion is a process independent on PPAR- activation and is
mediated by intracellular ROS, because it becomes enhanced
by Fenton chemistry-derived ROS and, in an opposite fashion,
significantly prevented by ROS scavengers, such as NAC (0.5–5
mM), TEMPO (100 M), and Me2SO (0.5%). In this context, we
have also found that allopurinol (1 mM), an inhibitor of xan-
thine oxidase activity, attenuates 15dPGJ2-dependent HO-1
expression and that 15dPGJ2 directly enhances xanthine oxi-
dase activity in a cell-free system. Finally, activations of the
PI3-kinase and p38 MAP kinase signaling pathways and acti-
vation of the transcription factor NF-B are shown to be intra-
cellular events mediating 15dPGJ2-dependent HO-1 expres-
sion, given that specific inhibitors of these proteins efficiently
prevent HO-1 synthesis.
Previous reports (62) have not established whether 15dPGJ2
elicits its anti-inflammatory effects in a PPAR--dependent or
-independent manner. However, it has been shown recently
that 15dPGJ2 still exerts anti-inflammatory actions in PPAR-
deficient mice (15). In this light, our results indicate that
15dPGJ2-promoted induction of HO-1 expression in human
lymphocytes involves PPAR--independent mechanisms, be-
cause classical ligands of PPAR-, such as troglitazone and
ciglitazone, fail to elicit HO-1 protein (Fig. 2A) or mRNA (Fig.
2B) synthesis. Moreover, we have observed that other cyclopen-
tenone prostaglandins, such as PGD2 (the precursor of
15dPGJ2) and PGA1 and PGA2, which do not interact with
PPAR- or any other nuclear receptor of the PPAR subfamily,
are also able to induce HO-1 mRNA expression (Fig. 2D) and
that PGD2 and PGA1, but not PGA2, also enhanced HO-1
protein synthesis (Fig. 2C). These results confirm that mecha-
nisms of HO-1 induction exist in human lymphocytes that are
PPAR-independent, and raise the possibility that 15dPGJ2 can
act through mechanisms unrelated to its binding to receptors of
FIG. 7. Effects of allopurinol on 15dPGJ2-dependent HO-1 expression in human lymphocytes and of 15dPGJ2 on xanthine oxidase
activity. A, cells were preincubated at 37 °C with the indicated doses of allopurinol for 1 h and then treated or not with 5 M 15dPGJ2 for 18 h.
Thereafter, the cells were lysed, and HO-1 and -actin protein levels were determined by Western blotting analysis. B, xanthine oxidase at the
indicated doses was incubated at 37 °C with vehicle (0.1% Me2SO) or 10 M 15dPGJ2 for 20 min. Uric acid production was then measured on the
basis of the absorbance at 293 nm. Plotted values are the mean  S.E. from three separate experiments.
15dPGJ2 Induces HO-1 Expression in Human Lymphocytes21934
the PPAR subfamily to elicit expression of the HO-1 gene.
Regarding the potential implication of ROS in 15dPGJ2-de-
pendent HO-1 expression, we have found that ROS scavengers,
such as NAC, TEMPO, and Me2SO, hinder the positive effect of
15dPGJ2 on HO-1 expression in human lymphocytes (Figs. 3A
and 4). Moreover, when lymphocytes are preincubated with
BSO, a glutathione synthesis inhibitor, 15dPGJ2-dependent
HO-1 expression levels are higher than in BSO-untreated cells
(Fig. 3B). Furthermore, we have shown that 15dPGJ2 is able to
enhance intracellular ROS production in human lymphocytes,
with little but still significant difference as compared with
control cells (Fig. 5). Here it must be noted that when lympho-
cytes are incubated with vehicle alone (0.1% Me2SO), an un-
specific enhancement of ROS production is detected. Although
we lack a clear explanation for this fact, it may be suggested
that the contact of cells with a plastic surface during their
isolation might be sufficient to elicit a partial intracellular
oxidative state. This unspecific rise in ROS levels contrasts
with classical observations in resting neutrophils, which in the
absence of stimuli display a very low ROS production rate (63).
However, in agreement with present data, a necessity for cau-
tion has been raised when using the DCFDA assay to measure
intracellular ROS production by leukocytic mixed populations
(54), in the sense that, given the limited intrinsic capacity of
lymphocytes to synthesize ROS (64), other enzyme systems
generating ROS not readily accessible to DCFDA could be
operative. In this context, it has been suggested recently that
ROS generated by lymphocytes include H2O2, singlet oxygen,
and OH, but not O2
. (53), thus indicating that at variance with
other circulating leukocytes (e.g. neutrophils) lymphocytes do
not exhibit potent enzyme systems for the promotion of intra-
cellular oxidative stress (65). Regarding Fenton chemistry, we
have demonstrated that the addition of Fe2 and Cu2 ions
notably enhances 15dPGJ2-dependent HO-1 expression and, in
contrast, 1,10-phenanthroline, a chelator of copper and iron
ions, abolishes this process (Fig. 6). Collectively, these results
strongly suggest that the positive effect of 15dPGJ2 on HO-1
expression requires the participation of intracellular ROS, and
that the oxygen radicals seemingly involved include O2
. and
other species generated via Fenton reactions, such as OH.
Further experiments have highlighted the possibility that cel-
lular xanthine oxidase could also constitute a main source of
the ROS acting as mediators of 15dPGJ2-dependent HO-1 ex-
pression. This hypothesis is supported both by the inhibitory
effect of allopurinol on this process and by the fact that
15dPGJ2 promotes an increase of xanthine oxidase activity in
vitro (Fig. 7). To our knowledge, this constitutes the first report
of a direct, positive effect of 15dPGJ2 on an enzyme system.
Other sources of ROS, such as NADPH oxidase, cytochrome
P-450, and the mitochondrial respiratory chain, which are
clearly associated with the production of ROS in most cell types
(53, 54), are not likely to be involved in the modulation of HO-1
production, because their respective inhibitors (HMAP, keto-
conazole, and rotenone) fail to affect 15dPGJ2-dependent HO-1
expression (data not shown). Taken together, our results are in
FIG. 8. Effect of PI3-kinase and MAP kinase inhibitors on 15dPGJ2-dependent HO-1 expression in human lymphocytes. Cells were
preincubated at 37 °C for 30 min in the absence or presence of 100 nM wortmannin, 20 M LY294002, 5 M SB203580, or 25 M PD098059 and then
treated or not with 10 M 15dPGJ2 for 4 h (A) or 5 M 15dPGJ2 for 4 h (C), or else preincubated with the indicated doses of SB203580 or PD098059
for 2 h and then treated or not with 5 M 15dPGJ2 for 18 h (B). Thereafter, the cells were lysed, and HO-1 and -actin protein levels were
determined by Western blotting analysis (A and B), and HO-1 and GAPDH mRNA levels were analyzed by RT-PCR (C).
FIG. 9. Effect of NF-B-blocking peptide SN50 on 15dPGJ2-de-
pendent HO-1 expression in human lymphocytes. Cells were pre-
incubated at 37 °C in the absence or presence of 13.5 M SN50 or
SN50M peptides for 2 h, and then treated or not with 5 M 15dPGJ2 for
18 h. Thereafter, the cells were lysed, and HO-1 and -actin protein
levels were determined by Western blotting analysis.
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agreement with previous studies postulating HO-1 expression
as an important cytoprotective mechanism against oxidative
stress. In this light, a common denominator characterizing the
prompt stimulation of HO-1 occurring under most circum-
stances, such as hypoxia, UVA radiation, and other forms of
oxidative stress, is a drastic change in the intracellular redox
status with a transient decrease in cellular reduced glutathione
levels (25, 30). Likewise, recent studies (11, 46) have estab-
lished a link between intracellular oxidative stress and the
effects elicited by 15dPGJ2, such as the activation of MAP
kinase cascades in astrocytes and preadipocytes, or the gener-
ation of protein-bound lipid peroxidation products and the de-
pletion of glutathione and glutathione peroxidase in human
neuroblastoma cells.
The existence of a relationship between the elevation of ROS
levels and the activation of downstream signaling routes, such
as the PI3-kinase and MAP kinase pathways (42, 57), is also
well accepted. Additionally, it has been shown recently that
oxygen constitutes the upstream elements of radicals necessary
for the activation of MAP kinases in response to 15dPGJ2 in
astrocytes and preadipocytes (11). Our results show that the
p38 MAP kinase inhibitor, SB203580, is able to prevent in a
dose-dependent manner 15dPGJ2-dependent HO-1 expression,
whereas the MEK1/2 inhibitor, PD098059, does not have such
an effect (Fig. 8). This suggests that activation of the p38 MAP
kinase, but not of ERK1/2, constitutes an upstream signal
necessary for 15dPGJ2-dependent HO-1 expression. Also, when
human lymphocytes are preincubated with PI3 kinase inhibi-
tors (wortmannin or LY294002), 15dPGJ2-dependent HO-1 ex-
pression fails to take place (Fig. 8), thus highlighting the in-
volvement of a PI3 kinase-dependent pathway in this process.
Other protein kinases, such as tyrosine kinases and protein
kinase C or the protein phosphatases 2A and 2B, do not appear
to mediate the modulation of HO-1 expression by 15dPGJ2,
because their inhibitors are unable to affect 15dPGJ2-depend-
ent HO-1 synthesis (data not shown). Finally, we have shown
that induction by 15dPGJ2 of HO-1 gene expression in human
lymphocytes is prevented by SN50, a peptide able to block
NF-B activation, suggesting that HO-1 transcription is de-
pendent on NF-B (Fig. 9). This result relates, in addition to
the aforementioned role of ROS in modulation of HO-1 expres-
sion, to the observation that the HO-1 gene promoter bears a
motif known as the heme-responsive element, to which NF-B
binds upon cell treatment with oxidative reagents, such as
H2O2 (58). Furthermore, it must be emphasized that the bind-
ing of NF-B to a number of target genes in T cells has been
proven to be redox-sensitive (66). However, our observations do
not allow us to discard the participation of other transcription
factors as mediators of 15dPGJ2 induction of HO-1 gene expres-
sion. In this context, the factors Nrf2 and AP-1, which are also
involved in HO-1 transcriptional activation (67, 68), are addi-
tional candidates to fulfill such a role.
In order to elicit its biological effects, prostaglandin 15dPGJ2
requires concentrations substantially higher (up to M) (8, 11,
17, 19, 22, 35, 46, 61) than those endogenously present at the
sites of inflammation (nM levels) (2); this suggests that obser-
vations reported previously (8, 11, 17, 19, 22, 35, 46, 61) on the
effects of this compound could be of pharmacological rather
than physiological relevance. Collectively, our results suggest
that the biological effects of 15dPGJ2 at pharmacological doses
on human lymphocytes involve, at least in part, the expression
of a well established anti-inflammatory mediator, HO-1, which
is induced by 15dPGJ2 through PPAR--independent mecha-
nisms. The likely participation of ROS in this process strength-
ens current hypotheses establishing a link between intracellu-
lar oxidative stress and the effects elicited by 15dPGJ2 on its
target cells, such as the activation of MAP kinase cascades, the
generation of protein-bound lipid peroxidation products, and
the reduction of glutathione and glutathione peroxidase levels
(11, 46).
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